JP2008524259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524259A5 JP2008524259A5 JP2007547044A JP2007547044A JP2008524259A5 JP 2008524259 A5 JP2008524259 A5 JP 2008524259A5 JP 2007547044 A JP2007547044 A JP 2007547044A JP 2007547044 A JP2007547044 A JP 2007547044A JP 2008524259 A5 JP2008524259 A5 JP 2008524259A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- methyl
- ethyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- -1 1-hydroxycyclopentyl Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 241000219198 Brassica Species 0.000 claims 1
- 235000003351 Brassica cretica Nutrition 0.000 claims 1
- 235000003343 Brassica rupestris Nutrition 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 229940121792 Thiazide diuretic Drugs 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000010460 mustard Nutrition 0.000 claims 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 0 CCC(CC)(c(cc1)cc(C)c1OC(*)C(C)(C(C)(C)C)O)c(cc1)cc(cc2)c1cc2C(O)=O Chemical compound CCC(CC)(c(cc1)cc(C)c1OC(*)C(C)(C(C)(C)C)O)c(cc1)cc(cc2)c1cc2C(O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63793004P | 2004-12-21 | 2004-12-21 | |
| PCT/US2005/046360 WO2006069153A2 (en) | 2004-12-21 | 2005-12-19 | Vitamin d receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524259A JP2008524259A (ja) | 2008-07-10 |
| JP2008524259A5 true JP2008524259A5 (https=) | 2009-02-19 |
Family
ID=36499582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547044A Pending JP2008524259A (ja) | 2004-12-21 | 2005-12-19 | ビタミンｄ受容体モジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7943795B2 (https=) |
| EP (1) | EP1836151B1 (https=) |
| JP (1) | JP2008524259A (https=) |
| AT (1) | ATE427295T1 (https=) |
| BR (1) | BRPI0519494A2 (https=) |
| CA (1) | CA2589664A1 (https=) |
| CY (1) | CY1109113T1 (https=) |
| DE (1) | DE602005013698D1 (https=) |
| DK (1) | DK1836151T3 (https=) |
| ES (1) | ES2322962T3 (https=) |
| IL (1) | IL183655A (https=) |
| MX (1) | MX2007007439A (https=) |
| PL (1) | PL1836151T3 (https=) |
| PT (1) | PT1836151E (https=) |
| SI (1) | SI1836151T1 (https=) |
| WO (1) | WO2006069153A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| CA2589667A1 (en) | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
| US9428447B2 (en) | 2011-12-21 | 2016-08-30 | The Royal Institution For The Advancement Of Learning/Mcgill University | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| FR2801307B1 (fr) | 1999-11-24 | 2002-12-06 | Galderma Res & Dev | Analogues de la vitamine d |
| SI1511740T1 (sl) | 2002-05-29 | 2009-12-31 | Lilly Co Eli | Modulatorji vitamin d receptorja tipa fenil-tiofen |
| DE60326082D1 (de) | 2002-11-22 | 2009-03-19 | Lilly Co Eli | Modulatoren von vitamin d rezeptoren |
| EP1587906A2 (en) | 2003-01-10 | 2005-10-26 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| WO2004063348A2 (en) | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators |
| ES2291981T3 (es) | 2003-11-20 | 2008-03-01 | Eli Lilly And Company | Moduladores del receptor de la vitamina d. |
| US7595345B2 (en) | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| CA2544857A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| WO2005051936A1 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Phenyl-furan compounds as vitamin d receptor modulators |
| WO2005051898A2 (en) | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| CA2589667A1 (en) | 2004-12-21 | 2006-06-29 | Eli Lilly And Company | Vitamin d receptor modulators |
-
2005
- 2005-12-19 DK DK05854992T patent/DK1836151T3/da active
- 2005-12-19 AT AT05854992T patent/ATE427295T1/de active
- 2005-12-19 ES ES05854992T patent/ES2322962T3/es not_active Expired - Lifetime
- 2005-12-19 BR BRPI0519494-6A patent/BRPI0519494A2/pt not_active IP Right Cessation
- 2005-12-19 PL PL05854992T patent/PL1836151T3/pl unknown
- 2005-12-19 DE DE602005013698T patent/DE602005013698D1/de not_active Expired - Lifetime
- 2005-12-19 US US11/721,109 patent/US7943795B2/en not_active Expired - Fee Related
- 2005-12-19 PT PT05854992T patent/PT1836151E/pt unknown
- 2005-12-19 EP EP05854992A patent/EP1836151B1/en not_active Expired - Lifetime
- 2005-12-19 SI SI200530713T patent/SI1836151T1/sl unknown
- 2005-12-19 MX MX2007007439A patent/MX2007007439A/es active IP Right Grant
- 2005-12-19 CA CA002589664A patent/CA2589664A1/en not_active Abandoned
- 2005-12-19 WO PCT/US2005/046360 patent/WO2006069153A2/en not_active Ceased
- 2005-12-19 JP JP2007547044A patent/JP2008524259A/ja active Pending
-
2007
- 2007-06-04 IL IL183655A patent/IL183655A/en not_active IP Right Cessation
-
2009
- 2009-05-29 CY CY20091100577T patent/CY1109113T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12338203B2 (en) | Urea compound for antagonizing LPA1 receptor | |
| JP2008524259A5 (https=) | ||
| CA2436220A1 (en) | New mandelic acid derivatives and their use as thrombin inhibitors | |
| PE20090475A1 (es) | Derivados de acidos fenoxiaceticos | |
| JP2010524963A5 (https=) | ||
| UY27173A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| EA013646B1 (ru) | Замещённые бензоилом серин-амиды | |
| AR036100A1 (es) | Derivados de naftil benzofurano sustituidos, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos que son inhibidores del inhibidor-1 activador de plasminogeno (pai-1) | |
| CA2665572C (en) | Self etching self priming aqueous dental adhesive composition | |
| JP2015536928A5 (https=) | ||
| JP2008524260A5 (https=) | ||
| WO2009007137A3 (en) | Pharmaceutical composition for topical application of poorly soluble compounds | |
| CA2544501A1 (en) | Vitamin d receptor modulators | |
| CN104926802B (zh) | 用于制备神经氨酸衍生物的方法 | |
| JP2013530202A5 (https=) | ||
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| JP2004059439A5 (https=) | ||
| JP2007512327A5 (https=) | ||
| CN118338914A (zh) | 包含氨基脂质化合物的组合物以及制备和使用其的方法 | |
| KR20140141904A (ko) | 신규한 항암활성을 갖는 사마필린a 유도체 및 이를 함유하는 약학적 조성물 | |
| RU2012136457A (ru) | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) | |
| NZ570711A (en) | 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof | |
| RU2004133388A (ru) | Новые соли | |
| ES2767583T3 (es) | Método para fabricar un compuesto de difluorolactona | |
| ES2396524A1 (es) | Intermedios versátiles y funcionalizados en la síntesis de vitamina D y nuevos derivados de vitamina D |